2023 World Conference on Lung Cancer (Posters)-P1.24. Exploring the Stability of Gut Microbiome and Its Association with the Prognosis of NSCLC Treated with Chemoraditherapy

P1.24. Exploring the Stability of Gut Microbiome and Its Association with the Prognosis of NSCLC Treated with Chemoraditherapy - PDF(Slides)

Back to course

Pdf Summary

A recent study explored the stability of the gut microbiome in non-small cell lung cancer (NSCLC) patients undergoing chemoradiotherapy and its association with prognosis. The study found that the stability of the gut microbiota is important for clinical outcomes in NSCLC patients.<br /><br />The researchers performed metagenome analysis on fecal samples from 19 NSCLC patients at four timepoints during their treatment. They used microbiota stability assessment via iterative clustering (microSTASIS) to estimate the stability of the microbiota. Based on the stability coefficients, the patients were divided into two groups: high stability (HS) and low stability (LS).<br /><br />The results showed that the gut microbiota in the HS group had less inter-patient variation compared to the LS group. However, this difference was not statistically significant. In terms of probiotics analysis, the HS group had a significantly higher Simpson index on the genus and species level compared to the LS group. The HS group was enriched with Faecalibacterium and Stenotrophomonas, while the LS group was enriched with Bifidobacterium, Ruminococcus, and Vibrio. Further analysis showed that Faecalibacterium prausnitzii was the most abundant species of probiotics, which was enriched in the HS group.<br /><br />There was no difference in taxonomic composition and diversity of pathogens between the two groups. However, clinical analysis showed that higher gut microbiome stability was associated with longer progression-free survival (PFS) in NSCLC patients.<br /><br />In conclusion, the study suggests that higher gut microbiome stability may be associated with better prognosis in NSCLC patients. Probiotics diversity and composition may play a role in maintaining the stability of the gut microbiome. These findings have potential therapeutic implications for NSCLC and further validation is needed.

Asset Subtitle

FangJie Liu

Meta Tag

Speaker FangJie Liu

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

gut microbiome

non-small cell lung cancer

chemoradiotherapy

prognosis

metagenome analysis

microbiota stability

probiotics analysis

Faecalibacterium prausnitzii

progression-free survival

therapeutic implications